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miR-155) is associated with lymphoid and epithelial cancers. Initial EBV infection alters
lymphocyte gene expression, inducing cellular proliferation and differentiation as the virus transitions
through consecutive latency transcription programs. Cellular microRNAs (miRNAs) are important regulators
of signaling pathways and are implicated in carcinogenesis. The extent to which EBV exploits cellular miRNAs
is unknown. Using micro-array analysis and quantitative PCR, we demonstrate differential expression of
cellular miRNAs in type III versus type I EBV latency including elevated expression of miR-21, miR-23a, miR-
24, miR-27a, miR-34a, miR-146a and b, and miR-155. In contrast, miR-28 expression was found to be lower in
type III latency. The EBV-mediated regulation of cellular miRNAs may contribute to EBV signaling and
associated cancers.
© 2008 Elsevier Inc. All rights reserved.Introduction
The Epstein–Barr virus (EBV) has been implicated in a variety of
lymphoid and epithelial cancers, including Burkitt's lymphoma,
Hodgkin's disease, post-transplant lymphoproliferative disease,
AIDS-associated immunoblastic lymphoma, and nasopharyngeal
carcinoma. This ubiquitous human herpes virus persists for the life
of its host by establishing latent infection predominantly in resting
memory B lymphocytes (Babcock et al., 1998; Miyashita et al., 1997).
The process by which EBV establishes latency in memory B cells is not
fully understood. In the model proposed by Thorley-Lawson and
colleagues (Thorley-Lawson, 2005), EBV establishes infection in naïve
B cells, and through successive viral transcription programs, drives theConsortium, Tulane University
Orleans, LA 70112, USA. Fax:
n), cfewell@tulane.edu
du (J. McBride),
,
l rights reserved.proliferation and differentiation of the cell into a memory B cell.
During this differentiation process, EBV expresses proteins that mimic
antigen activation of B cells and effectively bypass the normal host
signals that drive B cell differentiation. In a newly-infected naïve B cell,
EBV initiates the growth program (also referred to as latency type III),
and expresses a total of nine protein-coding genes (Kieff and
Rickinson, 2007). These proteins — Epstein–Barr nuclear antigen
(EBNA)-1, -2, -3a, -3b, -3c, and -LP, and latent membrane protein
(LMP)-1, -2a, and -2b, — contribute the surrogate proliferation,
migration, and survival signals that antigen-activated naïve B cells
receive. Escape of growth program-associated lymphoblasts from
normal immune surveillance in post-transplant and HIV-associated
immune-suppressed individuals leads to lymphoproliferative dis-
eases, demonstrating the oncogenic potential of this EBV transcrip-
tional program. The oncogenic potential of the EBV growth/latency III
program is also demonstrated by its expression in primary B cells
transformed in vitro by infectionwith EBV, which generates long-lived
replicating cell lines referred to as lymphoblastoid cell lines (LCLs).
According to Thorley-Lawson's model, as the EBV-infected cell
matures into a memory B cell, both the virus and the cell enter a
quiescent state. The virus becomes transcriptionally silent, allowing it to
Fig. 1. EBV latency gene expression pattern correlates with distinct cellular and viral miRNA expression proﬁles. Micro-array analysis of miRNA expression was performed on RNA
isolated from EBV infected, immortalized cell lines expressing viral latency patterns I (Akata, Rael, Mutu) or III (JY, IB4, Jijoye), and EBV negative cell lines (Mutu EBNA-1 dominant
negative clones, DG75). Eight separate total RNA pairs were hybridized to miRNA arrays, and the data was grouped for analysis. Cluster analysis of miRNAs differentially expressed
(ANOVA, pb0.01) among EBV negative, EBV positive/latency I and EBV positive/latency III cell lines is represented by heat map, with red elements representing higher expression and
green elements representing lower expression.
258 J.E. Cameron et al. / Virology 382 (2008) 257–266escape immune recognition and preventing the subsequent immune-
mediated destruction of the host cell (Hochberg and Thorley-Lawson,
2005). Homeostatic maintenance of the memory cell population drives
expression of EBNA-1 alone (latency program, or latency type I) during
cell replication in order to concurrently replicate the viral genome and
appropriately segregate the viral episomes into the daughter cells
(Hochberg et al., 2004; Yates, Warren, and Sugden, 1985).Both antigen-driven B cell activation and EBV-driven activation are
tightly regulated. Recently a new class of cellular regulatory elements,
the small non-coding microRNAs (miRNAs), has been shown to play
critical roles in a variety of cell signaling pathways. Through
incorporation of the ~22 nucleotide single-stranded mature miRNA
into the RNA-induced silencing complex (RISC) and subsequent
imperfect base pairing within the 3′ untranslated region (UTR) of
Fig. 2. EBV latency-associated differential expression of mature cellular miRNA demonstrated by quantitative (real-time) polymerase chain reaction (PCR). Expression of mature
cellular miRNA differentially regulated during EBV latency was quantiﬁed in a panel of immortalized B cell lines by real-time PCR. Total RNA from the following immortalized B cell
lines was isolated, poly-adenylated and transcribed into cDNA: a. EBV-positive, latency III cell lines Jijoye, JY, IB4, and X50-7; b. EBV-positive, latency I cell lines Akata, Rael and Mutu;
c. EBV negative Burkitt's lymphoma cell line DG75. The cDNAs were tested for mature cellular miRNA species by real-time, quantitative PCR in triplicate, and results were normalized
to U6 small nuclear RNA expression. (A–F) mature miRNAs miR-15a, miR-21, miR-23a, miR-24, miR-27a, and miR-146b expression, respectively.
1 MicroRNA array data has been deposited to the NCBI GEO (National Center for
Biotechnology InformationGeneExpressionOmnibus). Series accessionnumber isGSE13056.
259J.E. Cameron et al. / Virology 382 (2008) 257–266target messenger RNA transcripts, miRNAs suppress translation,
thereby regulating protein levels (He and Hannon, 2004). This
mechanism enables miRNAs to regulate processes such as growth,
differentiation and apoptosis. Expression proﬁling of human miRNAs
in different cellular contexts has demonstrated that distinct cell
phenotypes have unique miRNA signatures. For instance, B lympho-
cyte populations can be distinguished based on miRNA expression
proﬁle: miR-7, miR-9, and miR-155 are upregulated in activated B
cells, while miR-224 is upregulated andmiR-181a is downregulated in
memory B cells (Lawrie et al., 2008). Distinct miRNA expression
patterns have also been shown to distinguish normal cells from tumor
cells, and the constitutive upregulation of oncogenic miRNAs
(oncomirs) contributes to the maintenance of the tumor phenotype
(Calin and Croce, 2006). One such oncomir is miR-155, which causes
tumors in miR-155-transgenic mice (Costinean et al., 2006) and is
highly expressed inmultiple types of B cell lymphoma (Eis et al., 2005;
Kluiver et al., 2005; Metzler et al., 2004).Viruses often exploit cellular pathways in order to promote the viral
life cycle. We hypothesized that EBV actively regulates the expression
of cellular miRNAs to promote a favorable host environment for the
virus. Previous studies have shown a correlation between Epstein–Barr
virus type III latency and expression of miR-155 (Jiang, Lee, and
Schmittgen, 2006; Kluiver et al., 2006), and we have recently shown
that EBV latency gene expression drives expression of miR-155 (Yin et
al., 2008a). In addition, we have recently demonstrated that miR-146a
is also induced by EBV type III latency at least in part through the
latency-associated oncoprotein LMP-1 (Cameron et al., 2008). Finally,
work published byMrazek et al. (2007) suggests that EBVmay regulate
other cellular miRNAs in addition to miR-155 andmiR-146a. To further
investigate the potential contribution of EBV in regulating cellular
microRNAs, array proﬁling1 was performed in a panel of transformed B
260 J.E. Cameron et al. / Virology 382 (2008) 257–266cell lines displaying EBV type III and type I latency gene expression as
well as EBV negative derivatives of the type I cell line, Mutu I.
Results
EBV latency gene expression pattern correlates with distinct cellular and
viral microRNA expression proﬁles
Micro-array chips containing probes for 470 unique human
miRNAs and 108 unique viral miRNAs were used to obtain miRNA
expression proﬁles for a panel of lymphoma cell lines grown to
similar densities. Analysis of variance (ANOVA) was performed on
the data set across three groups: EBV type III latency (Jijoye, JY, IB4,
and X50-7), EBV type I latency (Akata, Rael, Mutu I), and EBV-
negative cell lines [Burkitt's lymphoma DG75 and EBV-negative
derivatives of Mutu I, EBNA-1 dominant-negative clones 1, 3, 6, and 9
(Cameron et al., 2008)]. Cluster analysis of microRNAs displaying
differential expression (p values of b0.01) is shown in Fig. 1. As
expected, expression of viral miRNAs was detected in EBV positive
but not EBV negative cell lines. A subset of viral miRNA genes were
not detected in the latency III cell line IB4, a lymphoblastoid cell line
(LCL) derived from the B95-8 virus, which carries a deletion in the
region of the EBV genome that encodes these viral BART genes (Cai
et al., 2006; Parker et al., 1990). Probes designed to detect expression
of the rhesus lymphocryptovirus (RhLCV) miRNAs (eg, rlcv-miR-rL1-
13) scoring positive in EBV-infected cells represent genetic homo-
logues of EBV (Cai et al., 2006).
Comparison of the array proﬁles of EBV-negative Mutu and EBV-
positive Mutu I cells indicated no marked changes in cellular miRNA
expression. In addition, inclusion of the latency I Burkitt's lymphoma
cell lines Akata and Rael in the EBV-positive group and Burkitt's
lymphoma DG75 in the EBV-negative group also failed to identify
consistent cellular miRNA expression differences between EBV-
positive/latency I and EBV-negative cells. These results suggest that
neither expression of EBNA-1 plus non-coding viral RNAs expressed
during type I latency, nor the retention of EBV episomes inﬂuences
expression of cellular miRNAs.
In contrast to EBV-positive versus EBV-negative Mutu I compar-
isons, cluster analysis indicated striking differences in cellular micro-
RNA expression between cells exhibiting type III and type I latency (Fig.
1). As expected,miR-155 andmiR-146awere among thosemiRNAs that
were expressed at substantially higher levels in latency III cells (1053-
fold and 267-fold, respectively). Of the 41 cellularmicroRNAs altered by
EBV latency phenotype, a subset (miR-15a, miR-21, miR-28, miR-34a,Fig. 3. (A) Ct values for qPCR analysis of maturemiR-28 in type I versus type III latency cells. (B
represent two distinct ampliﬁcation products, one at 72 °C and one at 77 °C.members of the miR-23a cluster [miR-23a, miR-24, and miR-27a], and
miR-146b) was selected for further investigation based largely on the
magnitude of the difference detected.
Quantitative (real-time) PCR validation of differential cellular
miRNA expression
Mammalian miRNAs are transcribed by RNA polymerase II into
long polyadenlyated primary transcripts (pri-miRNA), which are then
cleaved by the enzyme drosha to form a ~70 base-pair hairpin loop
structure (Kim, 2005). This precursor transcript (pre-miRNA) is then
exported from the nucleus via exportin-5, and is further cleaved by the
enzyme dicer into a small (21–25 nucleotide) duplex RNA molecule
containing the mature miRNA and its complement, denoted miRNA⁎.
To validate differential expression of selected miRNAs identiﬁed in the
miRNA arrays, qRT-PCR for mature miRNAs was performed. Latency
III-associated expression of miR-155 and miR-146a has previously
been reported by our group (Cameron et al., 2008; Yin et al., 2008a)
and others (Jiang, Lee, and Schmittgen, 2006; Kluiver et al., 2006) so
validation of type III associated expression of these twomicroRNAs are
not reported herein. As shown in Fig. 2, expression of mature miR-21,
members of the miR-23a cluster (miR-23a, miR-24 and miR-27a), and
miR-146b is higher in the type III cell lines Jijoye, JY, IB4 and X50-7
relative to the type I cell lines, Akata, Rael, and Mutu I. In contrast to
the array data, mature miR-15a expression in qPCR assays did not
correlate with EBV latency type. For quantiﬁcation of miR-34a
expression, analysis of the mature form was considered unreliable
due to poor PCR efﬁciency (data not shown). In addition, although
lower Ct values (higher expression) were obtained for mature miR-28
analysis in the type I cell lines versus the type III cell lines (Fig. 3A),
melt curve analysis demonstrated the detection of two different PCR
products (Fig. 3B). Interestingly, the PCR products with the melting
temperatures of 72 °C were exclusively detected in the latency I cell
lines, while PCR products with melting temperatures of 77 °C were
exclusively detected in the latency III cell lines. Cloning and
subsequent sequencing of the PCR products identiﬁed mature miR-
28 amplicon in the latency I reactions, and non-speciﬁc ampliﬁcation
of a segment of the β-actin gene in the latency III reactions. Since the
signal detected in the latency type III reactions does not represent
miR-28, the differential expression of mature miR-28 in type I versus
type III latency cells may be even greater than that represented by
qPCR analysis.
Due to the limitations encountered with qPCR detection of the
mature form of miR-28 and miR-34a, as well as the potential for) Dissociation (melt) curve analysis of maturemiR-28 ampliﬁcation products. Two peaks
261J.E. Cameron et al. / Virology 382 (2008) 257–266cross-reactivity between the closely-related miR-146a and miR-146b
mature miRNAs, qRT-PCR assays were designed to speciﬁcally
amplify the primary transcripts of these cellular miRNAs. Higher
expression of pri-miR-34a was observed in EBV latency III-expressing
cell lines (Fig. 4). MicroRNA-28 is derived from intronic sequences of
the protein coding lipoma preferred partner (LPP) transcript.
Substantial latency III-associated suppression of the miR-28 primary
LPP transcript was seen (Fig. 4) supporting the conclusions drawn
from the qPCR data for mature miR-28.
Expression of pri-miR-146b was not tightly latency-type asso-
ciated, despite latency III-associated increases in mature miR-146b. In
addition, the latency I Burkitt's lymphoma cell line Rael, while having
no detectable mature miR-146b, expressed readily detectable levels of
pri-miR-146b. This suggests a possible defect in miR-146b processingFig. 4. Cellular miRNA primary transcripts differentially regulated during EBV latency. Tran
miRNAs differentially regulated during EBV latency. Total RNA from the following immortal
lines Jijoye, JY, IB4, and X50-7; b. EBV-positive, latency I cell lines Akata, Rael and Mutu; c. E
mature cellular miRNA species by real-time, quantitative PCR in triplicate, and results were
pri-miR-21, pri-miR-28 (LPP transcript), pri-miR-34a and pri-miR-146b, respectively.in type I latency cells. However, at this time, we cannot rule out the
possibility that detection of mature miR-146b in type III latency cells is
due to cross reactivity with mature miR-146a. Nevertheless, we can
conclude that the transcription rate of the miR-146b gene and/or
stability of the miR-146b transcript is not substantially different in
type I vs type III latency cells.
Quantitative RT-PCR assays were also designed to assess the
primary transcript levels of miR-21 and the miR-23a cluster to
investigate whether differences in the levels of the mature micro-
RNAs is due to altered transcription rates or differences in post-
transcriptional processing. Three different primer pairs were
designed to amplify the primary miR-23a cluster transcript but all
of these failed to amplify a product using RNAs from type I or type III
cell lines. We believe that the inability to detect the miR-23a clusterscript-speciﬁc PCR primers were designed to amplify the primary transcript of cellular
ized B cell lines was isolated and transcribed into cDNA: a. EBV-positive, latency III cell
BV negative Burkitt's lymphoma cell lines DG75 and Ramos. The cDNAs were tested for
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. (A–D)
262 J.E. Cameron et al. / Virology 382 (2008) 257–266primary transcript may be attributable to efﬁcient processing of the
primary transcript resulting from the combined effect of processing
at the miR-23a, the miR-24, and the miR-27a loci. This idea is
supported by the separate ﬁnding that cloning the miR-23a cluster
immediately down stream from the GFP reading frame in a CMVFig. 5. EBV infection of primary B lymphocytes alters cellular miRNA primary transcript expr
in three low-passage LCL cell lines (Dana, Boston, Alewife). Total RNAwas reverse transcribed
pri-miR21, pri-miR28 (LPP transcript), pri-miR34a, pri-miR146a, and pri-miR146b expressio
triplicate.expression vector causes abrogation of GFP detection in transfected
cells (data not shown). Analysis of miR-21 primary transcript levels
demonstrated measurable expression in latency I cells and a
relatively modest 2-fold higher expression in latency III cells (Fig.
4) despite the more substantial increase in mature miR-21 detectionession. Expression of pri-miRNA in primary B lymphocytes was compared to expression
and the resulting cDNAwas assessed for pri-miRNA expression by real-time PCR. (A–E)
n, respectively. Data is normalized to 18S rRNA expression. All samples were tested in
263J.E. Cameron et al. / Virology 382 (2008) 257–266(10- to 35-fold, Fig. 2). This raises the possibility that higher
expression of mature miR-21 in type III latency cells may be elicited
in part through enhanced post-transcriptional microRNA processing
mechanisms.
Cellular miRNAs are regulated during EBV-induced transformation of
normal B lymphocytes
To further address the link between cellular miRNA expression
changes and EBV, expression of the panel of miRNAs was examined in
peripheral B lymphocytes isolated from a pool of normal, healthy
donors and three low-passage LCL lines (type III latency) generated by
infection of normal B cells with EBV. Lymphocytes (CD19-positive)
isolated from normal, healthy donors did not express detectable levels
of pri-miR-34a, pri-miR-146a or pri-miR-146b (Figs. 5C–E). These cells
also failed to express the mature forms of all three members of the
miR-23a cluster (Fig. 6A). Predicted levels of miR-92 and miR-150
were detected in the primary B cell sample (Lawrie et al., 2008),
indicating that the lack of detectable mature miR-23 cluster members
was not due to a lack of small RNAs in the sample (Fig. 6B). All three
low-passage LCLs demonstrated considerable levels of the primary
transcripts of miR-34a, miR-146a, miR-146b (Figs. 5C–E) and mature
miRNAs miR-23a, miR-24, and miR-27a (Fig. 6A). In contrast,
expression of the LPP transcript/miR-28 primary transcript was
markedly reduced (~90% reduction) in LCLs compared to the normal
lymphocytes (Fig. 5B). The primary transcript of miR-21, which was
expressed in all cell lines, was moderately increased (~2-fold) in LCLs
(Fig. 5A), while mature miR-21 expression was detected at 3–4 log
higher levels in LCLs. Despite detection of primary miR-21 transcripts
in peripheral B cells, mature miR-21 was not detected in these cells.
Like the primary and mature miR-21 analysis in type III versus type I
latency (above), this data also supports the notion that differential
expression of miR-21 is facilitated by a post-transcriptional processing
mechanism.
Discussion
In this study, we demonstrate that expression of the EBV latency III
transcription program modulates the expression of cellular miRNAs.Fig. 6.MaturemiR23 cluster expression is induced by EBV infection of primary B lymphocytes
were tested for mature miRNA expression by NCode real-time PCR. Samples were tested in tr
expression. (B) mature miR23a cluster expression. (C) Mature miR-92 (reportedly expressed s
normal, healthy lymphocytes, see Lawrie et al., 2008), demonstrating adequacy of peripherWe had previously described the regulation of cellular miR-155 and
miR-146a by EBV latency III transcriptional activity (Cameron et al.,
2008; Yin et al., 2008a), and we now demonstrate the regulation of
miR-21, miR-23a, miR-24, miR-27a, miR-28, miR-34a, and miR-146b.
Some of these results are consistent with a report published by
Mrazek et al., which sought to validate a novel subtractive hybridiza-
tion technique for identifying differentially-expressed noncoding
RNAs, using EBV-transformed and EBV-negative lymphoma cells as a
model (Mrazek et al., 2007). Despite the fact that Mrazek et al only
compared one pair of cells of dissimilar background (EBV-transformed
cord blood cells were compared to the EBV-negative Burkitt's
lymphoma cell line BL41), they observed higher expression of the
cellular miRNAs miR-21, miR-155, miR-146a, miR-23a, miR-27a, and
miR-34a in EBV-transformed cord blood lymphocytes. This study did
not detect more subtle changes in miRNA expression, such as the
upregulation of miR-146b, and the approach was not designed to
detect miRNAs downregulated by EBV expression such as miR-28. The
results reported herein expand the ﬁndings of Mrazek et al and
compliments their observations by demonstrating consistency in EBV-
mediatedmiRNA expression across a variety of cell backgrounds using
multiple, highly sensitive assays.
The differential expression of mature miR-21 was consistently
found to be greater than predicted by the more subtle differences in
pri-miR-21 expression in latency III phenotype cells versus type I
latency cells or uninfected B-cells. This discrepancy suggests that miR-
21 is processed more efﬁciently in type III latency cells. Importantly,
analysis of known viral and cellular miRNAs did not reveal any
miRNAs with sufﬁcient homology to miR-21 to be detected in our
assays (data not shown). Nevertheless, the possibility that EBV induces
the expression of another as yet unidentiﬁed cellular or viral miRNA
that shares signiﬁcant nucleotide homology with mature miR-21
cannot be ruled out.
A broad range of cellular mRNA transcripts may be targeted by a
single miRNA; likewise, a single mRNA transcript may be simulta-
neously regulated by multiple miRNAs. Regulation of cellular
pathways involves multiple miRNAs working in concert, and research
has only begun to identify some of the transcript targets of individual
miRNAs. Nevertheless, previously identiﬁed targets of the miRNAs
induced by EBVmay play a role in the interplay between the virus and. Peripheral B lymphocytes and low-passage lymphoblastoid cell lines (see Fig. 5 legend)
iplicate, and data is normalized to U6 small nuclear RNA expression. (A) mature miR-21
imilarly in all B cell subsets) and mature miR-150 expression (reportedly upregulated in
al B cell RNA for mature miRNA expression analysis.
Table 1
Primary miRNA transcript quantitative PCR primer sequences
Primer Primer Sequence, 5′-3′
U6 forward CTCGCTTCGGCAGCACA
U6 reverse AACGCTTCACGAATTTGCGT
Pri-miR-21 forward GTGACATCTCCATGGCTGTACCA
Pri-miR-21 reverse CAAAATGTCAGACAGCCCATCGAC
LPPex2 forward TCCACCTCTAGATGATTCCAGTG
LPPex2-3 reverse GGATTCCCCTGTACTTTGAAAGC
Pri-miR-34a forward CTTGAACTCCTGGCCTGAAG
Pre-miR-34a reverse GCCAAAGAAACACTCACAGCT
Pri-miR-146b forward GAGCAGCGTCCAGGCTGAA
Pre-miR-146b reverse CCGGGCACCAGAACTGAGT
264 J.E. Cameron et al. / Virology 382 (2008) 257–266the host cell. For instance, miR-24 has been demonstrated to promote
cell growth through repression of p16INK4a, consistent with the growth
phenotype of cells expressing EBV latency III transcripts (Lal et al.,
2008). The reported role of miR-34a in promoting p53-mediated
apoptosis is intriguing, given the complex regulatory role of EBV in
apoptotic pathways (Chang et al., 2007; He et al., 2007; Raver-Shapira
et al., 2007; Tarasov et al., 2007; Tazawa et al., 2007; Welch, Chen, and
Stallings, 2007).
The overexpression of miR-21 during EBV latency III has signiﬁcant
implications for both the EBV life cycle and EBV-mediated oncogenesis.
Upregulation of miR-21 has been demonstrated in metastatic breast,
colorectal, hepatocellular, cervical, pancreatic and glioblastoma cancers
(Asangani et al., 2008; Chan, Krichevsky, and Kosik, 2005; Frankel et al.,
2008; Lui et al., 2007; Meng et al., 2007; Volinia et al., 2006). In vitro,
ectopic expression ofmiR-21 promotes cell proliferation,migration and
invasion, and inhibition of miR-21 suppresses growth, migration, and
invasion, and increases apoptosis (Asangani et al., 2008; Chan,
Krichevsky, and Kosik, 2005; Frankel et al., 2008; Lofﬂer et al., 2007;
Lu et al., 2008; Meng et al., 2007; Si et al., 2007; Zhu et al., 2007; Zhu et
al., 2008). Several reports conﬁrmed that miR-21inhibits expression of
the tumor suppressors programmed cell death 4 (PDCD4) and
tropomyosin 1 (TPM1) (Asangani et al., 2008; Frankel et al., 2008; Lu
et al., 2008; Zhu et al., 2007; Zhu et al., 2008). Whether miR-21 inhibits
PDCD4 and/or TPM1 translation in the setting of EBV infected B
lymphocytes requires investigation.
Since the EBV-driven growth program of an infected naïve B cell
mimics the cellular program initiated upon antigen-driven activation,
it would be predicted that the miRNA proﬁles for these two events
would also be similar. In a study by Lawrie et al. (2008), the miRNA
proﬁle of B cells activated by either IL-2 or IgM treatment differed
from that of other B cell subsets (eg, naïve, germinal center, memory)
by increased expression of eleven miRNAs, including miR-7, miR-9,
miR-132, miR-155 and members of the 17–92 cluster (miR-17, miR-
20b and miR-106a) and decreased expression of miR-638. With the
exception of miR-155, known to be induced during B cell activation
through the activity of the transcription factor AP-1 (Yin et al., 2008b),
this proﬁle does not reﬂect that of EBV latency III-regulated miRNAs
identiﬁed in our study. This suggests that although EBV- and antigen-
activated B cell phenotypes are similar, the regulatory events of the
two pathways may be distinct. No direct comparison of miRNA
expression in antigen-activated and EBV-activated B cells has been
reported.
In summary, we have demonstrated that the EBV latency III
transcription (growth) program associated with initial infection in
vivo and lymphocyte transformation in vitro is associated with
changes in cellular miRNA expression. Two of these miRNAs, miR-
155 and miR-21, are putative oncogenes. The role of EBV-mediated
cellular miRNAs in EBV pathogenesis is currently under investigation.
Materials and methods
Maintenance of cell lines
Lymphocyte cell lines (latency III lymphoblastoid cell lines [LCLs] JY,
IB4, and X50-7; latency III Burkitt's lymphoma line Jijoye; latency I
Burkitt's lymphoma cell lines Akata, Rael, and Mutu; EBV-negative
Burkitt's lymphoma cell lines DG75, Ramos, and BL30; EBV-infected
Burkitt's lymphoma BL30/B95-8, and low-passage latency III LCL lines
Alewife, Boston, and Dana) were maintained in RPMI media plus 10%
fetal calf serum and 0.5% penicillin-streptomycin. Retrovirally
transduced EBNA-1 dominant negative (EBV negative) Mutu cells
were maintained in RPMI media plus 10% fetal calf serum, 0.5%
penicillin-streptomycin, 1 μg/ml puromycin, and 1 mg/ml gentamicin.
Generation of the EBNA-1 dominant negative expression plasmid and
EBNA-1 dominant negative Mutu cell lines has been detailed else-
where (Cameron et al., 2008).RNA isolation
RNAs used for miRNA array analysis and for quantifying mature
miRNAs were generated by a modiﬁed TRIzol method. Brieﬂy, 107 cells
were suspended in TRIzol reagent (Invitrogen) and processed as per
manufacturer's protocol up through the addition of isopropanol.
Samples were allowed to precipitate in isopropanol overnight at
−20 °C. Samples were then centrifuged at 12,000×g for 30 min at 4 °C.
Isopropanol was decanted and nucleic acid pellets were resuspended
in 200 μl nuclease-free water. RNA was then precipitated again by
adding 20 μl 3 M sodium acetate and 0.5 ml of 100% ethanol, and
incubating overnight at −20 °C. Samples were centrifuged at 12,000×g
for 30 min at 4 °C, ethanol was decanted, and samples were washed
once with 75% ethanol and allowed to air dry for no more than 10 min
RNA pellets were resuspended in nuclease-free water, quantiﬁed by
UV spectrophotometry, aliquoted, and stored at −80 °C.
Total RNA used for assessing the levels of primary miRNA
transcripts was isolated from 107 cells using a RNEasy kit (Qiagen)
according to the manufacturer's protocol. The RNA was eluted from
the column using 50 μl nuclease-free water, quantiﬁed by UV
spectrophotometry, and stored at −80 °C.
Primary B cell RNA used in comparison with EBV-infected primary
B lymphocytes was purchased from Miltenyi Biotec (Germany). This
sample consisted of total RNA isolated from CD19+ cells puriﬁed by
positive magnetic selection from buffy coat preparations from a pool
of healthy blood donors. Informed consent was obtained from
participating blood donors and the procedure adhered to the guide-
lines set forth by the GermanMedical Association, as well as pertinent
German and EU laws.
Quantitative (real-time) reverse transcription PCR (qRT-PCR) for mature
miRNA and primary transcript (pri-miRNA)
To quantify mature miRNA expression, total RNA isolated by a
modiﬁed TRIzol protocol (see RNA isolation) was poly-adenylated and
reverse-transcribed using the NCode miRNA First Strand Synthesis kit
(Invitrogen) according to the manufacturer's instructions. The result-
ing cDNA was subjected to quantitative (real-time) PCR using the
NCode universal reverse primer in conjunction with a sequence-
speciﬁc forward primer (forward primers for NCode miRNA detection
are the exact sequence of the mature miRNA). Similarly, U6 small
nuclear RNAwas quantiﬁed using the NCode universal reverse primer
and a U6-speciﬁc primer (5′-CTCGCTTCGGCAGCACA-3′), and all
mature miRNA data were normalized to the U6 data. A master mix
was prepared for each PCR run which included Platinum SYBR green
SuperMix plus UDG (Invitrogen), 50 nM ﬂuorescein-NIST traceable
dye, 100 nM forward and reverse primers, and nuclease-free water.
Ampliﬁcation consisted of 2 min at 50 °C, 2 min at 95 °C, followed by
40 cycles of 95 °C for 15 s and 60 °C for 30 s.
Total RNA prepared by Qiagen RNEasy column extraction was
DNAse treated and reverse transcribed using random hexamer
primers and SuperScript III reverse transcription enzyme mix and
265J.E. Cameron et al. / Virology 382 (2008) 257–266reagents (Invitrogen) according to the manufacturer's instructions.
Primary transcript expressionwasquantiﬁedusing speciﬁc forward and
reverse primers (see Table 1) at 200 nM concentration in a reaction
consisting of SYBR green SuperMix plus UDG, 50 nM ﬂuorescein-NIST
traceable dye, and nuclease-free water. Cycling parameters were as
follows: 2min at 50 °C, 2min at 95 °C, followed by 40 cycles of 95 °C for
30 s and 60 °C for 30 s . Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was quantiﬁed similarly and was used to normalize the pri-
miRNAdata; the primer sequences are published elsewhere (West et al.,
2004). In the case of the experiments comparing pri-miRNA transcript
expression in primary B cells compared to low-passage LCLs, GAPDH
was substantially lower in primary B cells, and data were instead
normalized to 18S rRNA expression, which was comparably expressed
in primary B cells and LCLs.
Melt curve analysis was performed at the end of every qRT-PCR
run. Samples were tested in triplicate. Real-time PCR was performed
on Bio-Rad iCyclers (MyIQ, IQ4 or IQ5) and data analysis was
performed using Bio-Rad IQ5 v2 software. Measures taken to prevent
and identify PCR contamination included maintaining a physically
separate, nucleic acid-free area with designated equipment for PCR
setup, and using both no-template controls and no-reverse transcrip-
tion controls in every experiment. A standard dilution curve,
generated by serially diluting a pooled stock of positive control
cDNAs, was included in each run. Experiments were repeated if
controls did not behave as predicted.
Relative expression was calculated for each test sample by the
standard curve method (for formulas, see ABI Prism 7700 Sequence
Detection System User Bulletin #2: Relative Quantitation of Gene
Expression, Applied Biosystems, Foster City, CA). Relative quantities of
each test sample were extrapolated from the standard curve run
concurrently with the sample, and the values were normalized to U6
small nuclear RNA (mature miRNA NCode assays), GAPDH or 18S rRNA
(primary transcript assays). The normalized values were then
compared to a calibrator sample within the run. Data are presented
as expressions relative to the calibrator, with the standard error of the
mean of the triplicate measures for each test sample.
Cellular miRNA micro-array analysis
Small RNA isolation and hybridization was performed by LC
Sciences (Houston, TX). Brieﬂy, small RNA species were isolated
from total RNA by column exclusion. The concentrated small RNAs
were 3′ poly-adenylated with poly (A) polymerase. A nucleotide tag
was then ligated to the poly-A tails. The tagged RNAs were hybridized
to a μParaﬂo superﬂuidic array chip containing probes for human and
viral miRNA sequences, and were subsequently labeled in a second
hybridization reaction with Cy3 and Cy5 dendrimer dyes. After
overnight hybridization, arrays were stringently washed and scanned
on an Axon GenePix 4000B laser scanner (Axon Instruments). Data
extraction and imaging were performed using ArrayPro software
(Media Cybernetics).
Each array compared an EBV latency type III-expressing cell line
(eg, JY, IB4, X50-7, Jijoye) to cells expressing EBV latency type I (Akata,
Rael, Mutu) or EBV positive Mutu cells to EBV negative Mutu cells
(Mutu E1dn clones). Eight separate arrays were performed. The most
up-to-date chip available for analysis was used (containing probes for
all human miRNA listed in Sanger Institute miRBase release 9.1,
totaling 470 unique miRNAs). Additional probes (108 unique
sequences) for viral miRNA expression were included on each chip.
Each probe was repeated in sextuplicate. Dye-swap experiments were
executed to control for labeling bias. Data within each individual chip
were adjusted by subtraction of background ﬂuorescence (calculated
as the median of the lower 5–25% of signal intensities) followed by
normalization of the data to the statistical median of all detectable
signals. Variation among arrays introduced by differences in experi-
mental conditions (ie, sample preparation, dye labeling, chip quality,and scanning variations) was corrected by normalization of the data
by the cyclic LOWESS (locally-weighted regression) method (Bolstad
et al., 2003). Intensity values were then Log2 transformed and further
normalized and centered using the equation: Value=[(Log2 intensity
value)− (Mean of values across all samples for the individual gene)] /
[(standard deviation of values across all samples for the individual
gene)]. The ratio of expression between paired samples was normal-
ized for clustering analysis by the equation: Value=[Log2 (Ratio)] /
[(standard deviation (Log2 (Ratio))]. Statistical comparison of paired
sample miRNA expression was performed using t-tests, and corre-
sponding p-values were calculated (Pan, 2002). MicroRNA showing
differential expression at the pb0.10, pb0.05 and pb0.01 were
selected for clustering analysis, which was performed using
hierarchical method based on average linkage and Euclidian distance
metric (Eisen et al., 1998). All data calculations were performed by LC
Sciences. Clustering plots were created using TIGR MeV (Multiple
Experimental Viewer) software (The Institute for Genomic Research).
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